-
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study
Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 31 Mar 2019, In: Haematologica. 104, 4, p. e151-e153Research output: Contribution to journal › Letter › Academic › peer-review
-
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
JULIET Investigators, Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & 18 others, 3 Jan 2019, In: New England journal of medicine. 380, 1, p. 45-56 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K. & Kersten, M. J., 2018, In: Blood Cancer Journal. 8, 2, p. 16 16.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications
